Learn More
PURPOSE Compare the pharmacokinetic (PK) profiles of immediate- and extended-release formulations of topiramate (TPM) in healthy subjects following multiple dosing, and evaluate maintenance of topiramate exposures after switching formulations. METHODS A randomized, open-label, single-center, two-way crossover, multiple-dose study comparing the(More)
Chronic administration of beta,beta'-iminodipropionitrile causes a persistent syndrome of excitement, choreoathetoid movements, and circling (the "ECC-syndrome") which persists indefinitely after termination of the IDPN injections. Ro 22-1319 is a specific D-2 dopamine receptor antagonist which was recently synthesized to fit a hypothetical model of the D-2(More)
The effects of drugs with selective action on alpha 1- or alpha 2-adrenoceptors were investigated on persistent head twitches, vertical neck dyskinesia, and the random circling behaviors induced by chronic intraperitoneal injections of IDPN. The alpha agonist clonidine and the alpha antagonist prazosin inhibited the IDPN-induced behavioral syndrome whereas(More)
OBJECTIVE Evaluate the pharmacokinetics (PK), safety, and tolerability of single doses of once-daily USL255, Qudexy XR (topiramate) extended-release capsules, over a wide dosing range. METHODS Two single-dose, phase I studies in healthy adults were used to evaluate the PK profile and maximum tolerated dose (MTD) of USL255 from 25-1,400 mg. Standard PK(More)
The effects of naltrexone on the persistent movement disorder induced in mice by the neurotoxic substance IDPN were examined. Naltrexone (2-4 mg/kg, IP) significantly reduced the hyperactivity and the stereotypic behaviors induced by IDPN. Fifteen minutes after the injection of naltrexone, the dyskinetic neck movements were almost completely inhibited at(More)
  • 1